StockFacets
About
Sign-up
Sign-in
Earnings Calendar
Prices are updated after-hours
Published
Previous years
63
This year
4
Publishing Date
2024 - 03 - 05
1
2024 - 02 - 15
1
2024 - 02 - 12
1
2024 - 02 - 02
1
2023 - 12 - 13
1
2023 - 11 - 03
1
2023 - 11 - 02
2
2023 - 10 - 25
2
2023 - 10 - 09
1
2023 - 10 - 06
1
2023 - 09 - 15
1
2023 - 09 - 13
2
2023 - 09 - 07
1
2023 - 08 - 03
1
2023 - 07 - 24
1
2023 - 07 - 19
1
2023 - 07 - 17
1
2023 - 06 - 30
1
2023 - 05 - 04
1
2023 - 04 - 26
2
2023 - 04 - 24
1
2023 - 03 - 08
1
2023 - 02 - 23
1
2023 - 02 - 21
2
2023 - 01 - 16
1
2022 - 12 - 21
1
2022 - 12 - 15
1
2022 - 12 - 08
1
2022 - 11 - 21
1
2022 - 11 - 03
1
2022 - 11 - 01
1
2022 - 09 - 20
1
2022 - 09 - 15
2
2022 - 09 - 13
2
2022 - 09 - 12
1
2022 - 09 - 08
1
2022 - 08 - 29
1
2022 - 08 - 24
1
2022 - 08 - 18
1
2022 - 08 - 03
1
2022 - 07 - 28
1
2022 - 07 - 27
2
2022 - 06 - 14
1
2022 - 06 - 09
1
2022 - 06 - 02
1
2022 - 05 - 24
1
2022 - 03 - 01
1
2022 - 02 - 10
1
2022 - 01 - 19
1
2021 - 12 - 22
1
2021 - 12 - 20
1
2021 - 12 - 14
1
2021 - 12 - 12
1
2021 - 11 - 05
1
2021 - 10 - 28
1
Sector
Commercial services
1
Consumer non-durables
1
Health technology
63
Manufacturing
3
Professional, scientific, and technical services
2
Tags
Active
1
Alliances
1
Als
1
Alzheimer
1
Alzheimer's
1
Alzheimer's disease
1
Alzheimer’s
5
America
1
Amvuttra
1
Application
9
Approval
2
Blood
2
Cardiovascular
2
Care
1
Children
1
Clinical-trials-phase-i
6
Clinical-trials-phase-iii
5
Companies
2
Day
2
Disease
8
Drug
6
Earnings
5
Europe
2
Events
2
Fda
6
Financial
8
Financial results
2
Food
4
Genetown
19
Global
2
Hypertension
2
Liver
2
Market
5
Meeting
3
N/a
13
Nash
2
Nephropathy
2
Offering
2
Ongoing
2
Onpattro
3
Oxlumo
2
Pharmaceutical
2
Pharmaceuticals
4
Phase 1
2
Phase 2
2
Phase 3
3
Pipeline
2
Positive
12
Publication
3
Report
7
Research
6
Results
23
Review
2
Risk
2
Study
11
Technology
2
Therapeutics
3
Topline
4
Treatment
17
Year
3
Entities
Abbott laboratories
221
Abbvie inc.
167
Alnylam pharmaceuticals, inc.
63
Alphabet inc.
37
Amarin corporation plc
36
Amgen inc.
132
Astellas pharma inc
70
Astrazeneca plc
177
Bausch health companies inc.
24
Baxter international inc.
41
Becton, dickinson and company
26
Biogen inc.
48
Biomarin pharmaceutical inc.
19
Biontech se
129
Boston scientific corporation
19
Bristol-myers squibb company
70
Byline bancorp, inc.
26
Csl ltd
22
Denali therapeutics inc.
19
Eli lilly and company
253
Endo international plc
18
Galapagos nv
41
Gilead sciences, inc.
35
Glaxosmithkline plc
273
Icon plc
12
Igm biosciences, inc.
37
Incyte corporation
102
Innate pharma s.a.
81
Innate pharma sa
81
Insulet corporation
15
Johnson & johnson
465
Kymera therapeutics, inc.
22
Medtronic plc
33
Mobiv acquisition corp
65
Moderna, inc.
22
Morgan stanley
14
Morphosys ag
38
Nektar therapeutics
44
Novartis ag
285
Novo nordisk a/s
100
Nurix therapeutics, inc.
14
Oncocyte corporation
37
Orange
49
Pegasus digital mobility acquisition corp.
17
Perrigo company
104
Pfizer, inc.
90
Provention bio, inc.
283
Ptc therapeutics, inc.
35
Rallybio corp
36
Rcf acquisition corp.
83
Reckitt benckiser group plc
21
Regeneron pharmaceuticals, inc.
189
Sanofi
3613
Takeda pharmaceutical company limited
51
Teva pharmaceutical industries limited
17
Teva pharmaceutical industries ltd
224
Therapeuticsmd, inc.
35
Thermo fisher scientific inc
36
Vaxart, inc.
36
Viatris inc.
81
Symbols
ABBV
12
ABEO
2
ABT
2
ACAD
4
ADAP
3
ADCT
5
AGIO
12
AGTC
2
ALKS
4
ALNY
243
ALPMF
2
ALPMY
2
ALT
2
AMGN
11
ARWR
2
AVEO
10
AXLA
2
BGNE
10
BIIB
5
BLUE
3
BMY
11
BPMC
14
CLVS
10
DHR
3
EDIT
4
EPZM
11
EXEL
14
GILD
6
ILMN
10
INCY
14
IONS
11
IRWD
4
JAZZ
4
JNJ
8
KPTI
10
LLY
38
MDGL
3
MRNA
6
NBIX
4
NTLA
4
NVO
25
NVS
5
NVSEF
5
PFE
14
PTCT
4
RARE
5
REGN
24
RIGL
10
RPRX
3
SAGE
4
SGMO
4
SNY
78
SNYNF
63
SRPT
8
TEVJF
4
UTHR
4
VIR
24
VSTM
10
XNCR
4
YMAB
10
Exchanges
Nasdaq
63
Nyse
6
Crawled Date
2024 - 03 - 05
1
2024 - 02 - 15
1
2024 - 02 - 12
1
2024 - 02 - 02
1
2023 - 12 - 13
1
2023 - 11 - 03
1
2023 - 11 - 02
2
2023 - 10 - 25
2
2023 - 10 - 09
1
2023 - 10 - 06
1
2023 - 09 - 15
1
2023 - 09 - 13
2
2023 - 09 - 07
1
2023 - 08 - 03
1
2023 - 07 - 24
1
2023 - 07 - 19
1
2023 - 07 - 17
1
2023 - 06 - 30
1
2023 - 05 - 04
1
2023 - 04 - 26
2
2023 - 04 - 24
1
2023 - 03 - 08
1
2023 - 02 - 23
1
2023 - 02 - 21
2
2023 - 01 - 16
1
2022 - 12 - 21
1
2022 - 12 - 15
1
2022 - 12 - 08
1
2022 - 11 - 21
1
2022 - 11 - 03
1
2022 - 11 - 01
1
2022 - 09 - 20
1
2022 - 09 - 15
2
2022 - 09 - 13
2
2022 - 09 - 12
1
2022 - 09 - 08
1
2022 - 08 - 29
1
2022 - 08 - 24
1
2022 - 08 - 18
1
2022 - 08 - 03
1
2022 - 07 - 28
1
2022 - 07 - 27
2
2022 - 06 - 14
1
2022 - 06 - 09
1
2022 - 06 - 02
1
2022 - 05 - 24
1
2022 - 03 - 01
1
2022 - 02 - 10
1
2022 - 01 - 19
1
2021 - 12 - 22
1
2021 - 12 - 20
1
2021 - 12 - 14
1
2021 - 12 - 12
1
2021 - 11 - 05
1
2021 - 10 - 28
1
Crawled Time
06:00
1
07:00
1
08:00
1
09:00
1
10:00
1
11:00
3
12:00
8
12:20
2
12:30
2
13:00
11
13:20
1
13:30
1
14:00
5
14:30
4
15:00
3
16:00
6
19:00
1
20:00
1
20:20
1
21:00
1
22:00
5
23:00
3
Source
www.alnylam.com
1
www.biospace.com
50
www.globenewswire.com
5
www.prnewswire.com
7
Sort by:
after hours % change
|
delayed % change
|
gain open
|
gain high
|
gain close
|
publishing date
(GMT-12:00) International Date Line West
(GMT-11:00) American Samoa
(GMT-11:00) Midway Island
(GMT-10:00) Hawaii
(GMT-09:00) Alaska
(GMT-08:00) Pacific Time (US & Canada)
(GMT-08:00) Tijuana
(GMT-07:00) Arizona
(GMT-07:00) Chihuahua
(GMT-07:00) Mazatlan
(GMT-07:00) Mountain Time (US & Canada)
(GMT-06:00) Central America
(GMT-06:00) Central Time (US & Canada)
(GMT-06:00) Guadalajara
(GMT-06:00) Mexico City
(GMT-06:00) Monterrey
(GMT-06:00) Saskatchewan
(GMT-05:00) Bogota
(GMT-05:00) Eastern Time (US & Canada)
(GMT-05:00) Indiana (East)
(GMT-05:00) Lima
(GMT-05:00) Quito
(GMT-04:00) Atlantic Time (Canada)
(GMT-04:00) Caracas
(GMT-04:00) Georgetown
(GMT-04:00) La Paz
(GMT-04:00) Puerto Rico
(GMT-04:00) Santiago
(GMT-03:30) Newfoundland
(GMT-03:00) Brasilia
(GMT-03:00) Buenos Aires
(GMT-03:00) Greenland
(GMT-03:00) Montevideo
(GMT-02:00) Mid-Atlantic
(GMT-01:00) Azores
(GMT-01:00) Cape Verde Is.
(GMT+00:00) Casablanca
(GMT+00:00) Dublin
(GMT+00:00) Edinburgh
(GMT+00:00) Lisbon
(GMT+00:00) London
(GMT+00:00) Monrovia
(GMT+00:00) UTC
(GMT+01:00) Amsterdam
(GMT+01:00) Belgrade
(GMT+01:00) Berlin
(GMT+01:00) Bern
(GMT+01:00) Bratislava
(GMT+01:00) Brussels
(GMT+01:00) Budapest
(GMT+01:00) Copenhagen
(GMT+01:00) Ljubljana
(GMT+01:00) Madrid
(GMT+01:00) Paris
(GMT+01:00) Prague
(GMT+01:00) Rome
(GMT+01:00) Sarajevo
(GMT+01:00) Skopje
(GMT+01:00) Stockholm
(GMT+01:00) Vienna
(GMT+01:00) Warsaw
(GMT+01:00) West Central Africa
(GMT+01:00) Zagreb
(GMT+01:00) Zurich
(GMT+02:00) Athens
(GMT+02:00) Bucharest
(GMT+02:00) Cairo
(GMT+02:00) Harare
(GMT+02:00) Helsinki
(GMT+02:00) Jerusalem
(GMT+02:00) Kaliningrad
(GMT+02:00) Kyiv
(GMT+02:00) Pretoria
(GMT+02:00) Riga
(GMT+02:00) Sofia
(GMT+02:00) Tallinn
(GMT+02:00) Vilnius
(GMT+03:00) Baghdad
(GMT+03:00) Istanbul
(GMT+03:00) Kuwait
(GMT+03:00) Minsk
(GMT+03:00) Moscow
(GMT+03:00) Nairobi
(GMT+03:00) Riyadh
(GMT+03:00) St. Petersburg
(GMT+03:30) Tehran
(GMT+04:00) Abu Dhabi
(GMT+04:00) Baku
(GMT+04:00) Muscat
(GMT+04:00) Samara
(GMT+04:00) Tbilisi
(GMT+04:00) Volgograd
(GMT+04:00) Yerevan
(GMT+04:30) Kabul
(GMT+05:00) Ekaterinburg
(GMT+05:00) Islamabad
(GMT+05:00) Karachi
(GMT+05:00) Tashkent
(GMT+05:30) Chennai
(GMT+05:30) Kolkata
(GMT+05:30) Mumbai
(GMT+05:30) New Delhi
(GMT+05:30) Sri Jayawardenepura
(GMT+05:45) Kathmandu
(GMT+06:00) Almaty
(GMT+06:00) Astana
(GMT+06:00) Dhaka
(GMT+06:00) Urumqi
(GMT+06:30) Rangoon
(GMT+07:00) Bangkok
(GMT+07:00) Hanoi
(GMT+07:00) Jakarta
(GMT+07:00) Krasnoyarsk
(GMT+07:00) Novosibirsk
(GMT+08:00) Beijing
(GMT+08:00) Chongqing
(GMT+08:00) Hong Kong
(GMT+08:00) Irkutsk
(GMT+08:00) Kuala Lumpur
(GMT+08:00) Perth
(GMT+08:00) Singapore
(GMT+08:00) Taipei
(GMT+08:00) Ulaanbaatar
(GMT+09:00) Osaka
(GMT+09:00) Sapporo
(GMT+09:00) Seoul
(GMT+09:00) Tokyo
(GMT+09:00) Yakutsk
(GMT+09:30) Adelaide
(GMT+09:30) Darwin
(GMT+10:00) Brisbane
(GMT+10:00) Canberra
(GMT+10:00) Guam
(GMT+10:00) Hobart
(GMT+10:00) Melbourne
(GMT+10:00) Port Moresby
(GMT+10:00) Sydney
(GMT+10:00) Vladivostok
(GMT+11:00) Magadan
(GMT+11:00) New Caledonia
(GMT+11:00) Solomon Is.
(GMT+11:00) Srednekolymsk
(GMT+12:00) Auckland
(GMT+12:00) Fiji
(GMT+12:00) Kamchatka
(GMT+12:00) Marshall Is.
(GMT+12:00) Wellington
(GMT+12:45) Chatham Is.
(GMT+13:00) Nuku'alofa
(GMT+13:00) Samoa
(GMT+13:00) Tokelau Is.
entities :
Alnylam pharmaceuticals, inc.
symbols :
SNYNF
save search
Alnylam Reports Positive KARDIA-2 Topline Study Results Demonstrating Clinically Significant Blood Pressure Reductions When Zilebesiran is Added to Standard of Care Antihypertensives
Published:
2024-03-05
(Crawled : 16:00)
- biospace.com/
SNY
|
News
|
$47.69
1.15%
1.13%
1.1K
|
Health Technology
|
0.13%
|
O:
1.17%
H:
0.0%
C:
0.0%
ALNY
|
$146.07
0.19%
0.18%
0
|
Health Technology
|
-2.65%
|
O:
-0.73%
H:
1.52%
C:
0.5%
positive
blood
care
topline
results
study
Alnylam Pharmaceuticals Reports Fourth Quarter and Full Year 2023 Financial Results and Highlights Recent Period Activity
Published:
2024-02-15
(Crawled : 14:30)
- biospace.com/
SNYNF
|
News
|
$94.25
1.67%
-2.18%
0
|
Health Technology
|
4.2%
|
O:
1.16%
H:
1.48%
C:
0.89%
SNY
|
News
|
$47.69
1.15%
1.13%
1.1K
|
Health Technology
|
3.07%
|
O:
1.86%
H:
0.0%
C:
0.0%
ALNY
|
$146.07
0.19%
0.18%
0
|
Health Technology
|
-11.01%
|
O:
-8.62%
H:
2.18%
C:
-1.71%
year
pharmaceuticals
financial
results
Liver Disease Therapeutics Competitive Landscape and Market Forecasts to 2028
Published:
2024-02-12
(Crawled : 20:00)
- prnewswire.com
ALPMY
|
News
|
$9.49
-0.42%
55K
|
Manufacturing
|
-12.29%
|
O:
0.37%
H:
0.74%
C:
0.28%
BMY
|
$48.72
-0.55%
250K
|
Health Technology
|
-1.53%
|
O:
-0.18%
H:
0.48%
C:
-1.91%
ABBV
|
News
|
$168.48
-0.63%
110K
|
Health Technology
|
-2.04%
|
O:
0.8%
H:
0.0%
C:
0.0%
SNY
|
News
|
$47.69
1.15%
1.13%
1.1K
|
Health Technology
|
1.86%
|
O:
-0.06%
H:
0.0%
C:
0.0%
GILD
|
$66.45
-0.87%
380K
|
Health Technology
|
-9.97%
|
O:
0.32%
H:
0.11%
C:
-1.55%
ALNY
|
$146.07
0.19%
0.18%
0
|
Health Technology
|
-13.74%
|
O:
-2.63%
H:
0.98%
C:
-1.75%
liver
disease
therapeutics
market
Regeneron Reports Fourth Quarter and Full Year 2023 Financial and Operating Results
Published:
2024-02-02
(Crawled : 12:00)
- globenewswire.com
TSVT
|
$4.63
-0.43%
-0.43%
62
|
|
-10.79%
|
O:
-1.16%
H:
9.94%
C:
2.34%
SNY
|
News
|
$47.69
1.15%
1.13%
1.1K
|
Health Technology
|
-2.89%
|
O:
-0.93%
H:
0.0%
C:
0.0%
REGN
|
News
|
$907.32
0.8%
0.74%
460
|
Health Technology
|
-5.27%
|
O:
1.4%
H:
0.28%
C:
-2.68%
ALNY
|
$146.07
0.19%
0.18%
0
|
Health Technology
|
-16.49%
|
O:
-1.23%
H:
1.0%
C:
0.17%
year
financial
results
Alnylam Highlights Significant Progress with Platform Innovation and Clinical Pipeline at R&D Day
Published:
2023-12-13
(Crawled : 14:30)
- biospace.com/
SNYNF
|
News
|
$94.25
1.67%
-2.18%
0
|
Health Technology
|
0.52%
|
O:
-0.06%
H:
2.36%
C:
2.36%
SNY
|
News
|
$47.69
1.15%
1.13%
1.1K
|
Health Technology
|
-0.74%
|
O:
-0.27%
H:
2.28%
C:
2.16%
ALNY
|
$146.07
0.19%
0.18%
0
|
Health Technology
|
-15.99%
|
O:
-0.14%
H:
4.22%
C:
3.97%
day
innovation
pipeline
platform
Regeneron to Highlight Scientific Advancements Across Diversified Pipeline in Difficult-to-Treat Blood Cancers and Disorders at ASH
Published:
2023-11-03
(Crawled : 11:00)
- globenewswire.com
SNYNF
|
News
|
$94.25
1.67%
-2.18%
0
|
Health Technology
|
1.89%
|
O:
-1.79%
H:
0.0%
C:
0.0%
SNY
|
News
|
$47.69
1.15%
1.13%
1.1K
|
Health Technology
|
0.11%
|
O:
-3.04%
H:
0.0%
C:
0.0%
REGN
|
News
|
$907.32
0.8%
0.74%
460
|
Health Technology
|
10.81%
|
O:
2.37%
H:
0.12%
C:
-2.54%
ALNY
|
$146.07
0.19%
0.18%
0
|
Health Technology
|
-9.57%
|
O:
1.95%
H:
2.7%
C:
1.62%
disorders
pipeline
blood
Alnylam Pharmaceuticals Reports Third Quarter 2023 Financial Results and Highlights Recent Period Activity
Published:
2023-11-02
(Crawled : 13:00)
- biospace.com/
SNY
|
News
|
$47.69
1.15%
1.13%
1.1K
|
Health Technology
|
3.11%
|
O:
3.0%
H:
0.0%
C:
0.0%
ALNY
|
$146.07
0.19%
0.18%
0
|
Health Technology
|
-6.96%
|
O:
3.4%
H:
0.57%
C:
-0.5%
pharmaceuticals
financial
results
Regeneron Reports Third Quarter 2023 Financial and Operating Results
Published:
2023-11-02
(Crawled : 11:00)
- globenewswire.com
SNY
|
News
|
$47.69
1.15%
1.13%
1.1K
|
Health Technology
|
3.11%
|
O:
3.0%
H:
0.0%
C:
0.0%
REGN
|
News
|
$907.32
0.8%
0.74%
460
|
Health Technology
|
14.67%
|
O:
0.08%
H:
4.96%
C:
3.4%
NTLA
|
$21.53
-1.37%
-1.37%
0
|
Health Technology
|
-15.57%
|
O:
2.35%
H:
1.63%
C:
1.46%
ALNY
|
$146.07
0.19%
0.18%
0
|
Health Technology
|
-6.96%
|
O:
3.4%
H:
0.57%
C:
-0.5%
financial
results
Alnylam Announces Publication of Results from APOLLO-B Phase 3 Study of Patisiran in Patients with the Cardiomyopathy of ATTR Amyloidosis in the New England Journal of Medicine
Published:
2023-10-25
(Crawled : 23:00)
- biospace.com/
SNYNF
|
News
|
$94.25
1.67%
-2.18%
0
|
Health Technology
|
-8.94%
|
O:
0.4%
H:
1.29%
C:
1.29%
SNY
|
News
|
$47.69
1.15%
1.13%
1.1K
|
Health Technology
|
-10.17%
|
O:
1.43%
H:
0.64%
C:
-0.09%
ALNY
|
$146.07
0.19%
0.18%
0
|
Health Technology
|
-10.91%
|
O:
-1.28%
H:
0.58%
C:
-1.46%
publication
results
study
Alnylam Reports Additional Positive Interim Phase 1 Results for ALN-APP, in Development for Alzheimer’s Disease and Cerebral Amyloid Angiopathy
Published:
2023-10-25
(Crawled : 19:00)
- biospace.com/
SNYNF
|
News
|
$94.25
1.67%
-2.18%
0
|
Health Technology
|
-8.94%
|
O:
0.4%
H:
1.29%
C:
1.29%
SNY
|
News
|
$47.69
1.15%
1.13%
1.1K
|
Health Technology
|
-10.17%
|
O:
1.43%
H:
0.64%
C:
-0.09%
ALNY
|
$146.07
0.19%
0.18%
0
|
Health Technology
|
-10.91%
|
O:
-1.28%
H:
0.58%
C:
-1.46%
disease
alzheimer’s
positive
results
Alnylam Announces Receipt of Complete Response Letter from U.S. FDA for Supplemental New Drug Application for Patisiran for the Treatment of the Cardiomyopathy of ATTR Amyloidosis
Published:
2023-10-09
(Crawled : 14:30)
- biospace.com/
SNY
|
News
|
$47.69
1.15%
1.13%
1.1K
|
Health Technology
|
-12.64%
|
O:
0.19%
H:
0.0%
C:
0.0%
ALNY
|
$146.07
0.19%
0.18%
0
|
Health Technology
|
-17.44%
|
O:
-4.06%
H:
2.17%
C:
-0.83%
fda
drug
treatment
application
response
Alnylam to Present Additional Data for Patisiran in Patients With the Cardiomyopathy of ATTR Amyloidosis
Published:
2023-10-06
(Crawled : 13:00)
- biospace.com/
SNY
|
News
|
$47.69
1.15%
1.13%
1.1K
|
Health Technology
|
-12.8%
|
O:
-0.19%
H:
0.0%
C:
0.0%
ALNY
|
$146.07
0.19%
0.18%
0
|
Health Technology
|
-18.26%
|
O:
-0.16%
H:
1.44%
C:
-0.84%
RNA Therapeutics Market worth $18.0 billion | MarketsandMarkets
Published:
2023-09-15
(Crawled : 15:00)
- prnewswire.com
SNYNF
|
News
|
$94.25
1.67%
-2.18%
0
|
Health Technology
|
-13.01%
|
O:
1.53%
H:
0.0%
C:
0.0%
NVSEF
|
News
|
$96.0
0.94%
0
|
Health Technology
|
13.27%
|
O:
0.79%
H:
0.0%
C:
0.0%
ALPMY
|
News
|
$9.49
-0.42%
55K
|
Manufacturing
|
-36.69%
|
O:
3.0%
H:
0.0%
C:
-3.43%
PFE
|
News
4
|
$26.32
0.23%
0.15%
88K
|
Health Technology
|
-22.93%
|
O:
-0.26%
H:
1.04%
C:
0.03%
NVS
|
News
|
$97.28
2.27%
1.47%
190K
|
Health Technology
|
-2.92%
|
O:
1.51%
H:
0.26%
C:
-0.72%
SRPT
|
$117.12
0.14%
0.09%
31
|
Health Technology
|
-2.17%
|
O:
-0.27%
H:
0.54%
C:
-0.84%
SNY
|
News
|
$47.69
1.15%
1.13%
1.1K
|
Health Technology
|
-13.73%
|
O:
0.82%
H:
0.0%
C:
0.0%
MRNA
|
News
S
|
$107.89
3.28%
3.87%
33K
|
Health Technology
|
-4.36%
|
O:
0.16%
H:
2.0%
C:
1.42%
IONS
|
$41.84
1.88%
1.86%
260
|
Health Technology
|
-4.12%
|
O:
-0.57%
H:
0.35%
C:
-1.11%
BNTX
|
News
|
$88.49
0.55%
0.59%
1K
|
Health Technology
|
-22.25%
|
O:
0.17%
H:
0.48%
C:
-0.82%
ARWR
|
$23.78
-0.59%
-0.61%
50
|
Health Technology
|
-22.13%
|
O:
0.16%
H:
0.46%
C:
-5.46%
ALNY
|
$146.07
0.19%
0.18%
0
|
Health Technology
|
-24.34%
|
O:
-0.74%
H:
2.42%
C:
-3.47%
therapeutics
market
Alnylam Announces Positive Outcome of FDA Advisory Committee Meeting on Patisiran for the Treatment of the Cardiomyopathy of ATTR Amyloidosis
Published:
2023-09-13
(Crawled : 22:00)
- biospace.com/
SNYNF
|
News
|
$94.25
1.67%
-2.18%
0
|
Health Technology
|
-13.88%
|
O:
-1.8%
H:
0.0%
C:
0.0%
SNY
|
News
|
$47.69
1.15%
1.13%
1.1K
|
Health Technology
|
-14.08%
|
O:
-0.99%
H:
0.0%
C:
0.0%
fda
positive
treatment
meeting
Alnylam Stock Trading Halted Today; FDA Advisory Committee to Review Supplemental New Drug Application for Patisiran for the Treatment of the Cardiomyopathy of ATTR Amyloidosis
Published:
2023-09-13
(Crawled : 12:00)
- biospace.com/
SNYNF
|
News
|
$94.25
1.67%
-2.18%
0
|
Health Technology
|
-13.88%
|
O:
-1.8%
H:
0.0%
C:
0.0%
SNY
|
News
|
$47.69
1.15%
1.13%
1.1K
|
Health Technology
|
-14.08%
|
O:
-0.99%
H:
0.0%
C:
0.0%
fda
drug
review
treatment
application
Alnylam Reports Positive Topline Results from KARDIA-1 Phase 2 Dose-Ranging Study of Zilebesiran, an Investigational RNAi Therapeutic in Development to Treat Hypertension in Patients at High Cardiovascular Risk
Published:
2023-09-07
(Crawled : 14:30)
- biospace.com/
SNY
|
News
|
$47.69
1.15%
1.13%
1.1K
|
Health Technology
|
-10.67%
|
O:
1.03%
H:
0.0%
C:
0.0%
ALNY
|
$146.07
0.19%
0.18%
0
|
Health Technology
|
-27.49%
|
O:
-0.15%
H:
1.32%
C:
-0.02%
positive
treat
risk
topline
hypertension
cardiovascular
results
study
Alnylam Pharmaceuticals Reports Second Quarter 2023 Financial Results and Highlights Recent Period Activity
Published:
2023-08-03
(Crawled : 13:00)
- biospace.com/
SNYNF
|
News
|
$94.25
1.67%
-2.18%
0
|
Health Technology
|
-8.54%
|
O:
-1.6%
H:
0.11%
C:
0.11%
SNY
|
News
|
$47.69
1.15%
1.13%
1.1K
|
Health Technology
|
-9.75%
|
O:
-3.79%
H:
0.0%
C:
0.0%
ALNY
|
$146.07
0.19%
0.18%
0
|
Health Technology
|
-20.88%
|
O:
-1.35%
H:
5.58%
C:
4.38%
pharmaceuticals
financial
results
Alnylam Announces Partnership with Roche to Co-Develop and Co-Commercialize Zilebesiran, an Investigational RNAi Therapeutic for the Treatment of Hypertension in Patients with High Cardiovascular Risk
Published:
2023-07-24
(Crawled : 06:00)
- biospace.com/
SNY
|
News
|
$47.69
1.15%
1.13%
1.1K
|
Health Technology
|
-14.13%
|
O:
-0.88%
H:
0.0%
C:
0.0%
ALNY
|
$146.07
0.19%
0.18%
0
|
Health Technology
|
-27.72%
|
O:
0.06%
H:
0.0%
C:
0.0%
partnership
treatment
risk
hypertension
roche
cardiovascular
Alnylam Announces Publication of Phase 1 Study Results for Zilebesiran in the New England Journal of Medicine
Published:
2023-07-19
(Crawled : 22:00)
- biospace.com/
SNY
|
News
|
$47.69
1.15%
1.13%
1.1K
|
Health Technology
|
-11.96%
|
O:
0.88%
H:
0.0%
C:
0.0%
ALNY
|
$146.07
0.19%
0.18%
0
|
Health Technology
|
-29.92%
|
O:
0.74%
H:
0.28%
C:
-2.21%
publication
results
study
Alnylam Reports Updated Positive Interim Phase 1 Results for ALN-APP, in Development for Alzheimer’s Disease and Cerebral Amyloid Angiopathy
Published:
2023-07-17
(Crawled : 09:00)
- biospace.com/
SNY
|
News
|
$47.69
1.15%
1.13%
1.1K
|
Health Technology
|
-10.72%
|
O:
0.02%
H:
0.0%
C:
0.0%
REGN
|
News
|
$907.32
0.8%
0.74%
460
|
Health Technology
|
26.28%
|
O:
0.05%
H:
1.33%
C:
0.38%
ALNY
|
$146.07
0.19%
0.18%
0
|
Health Technology
|
-25.89%
|
O:
5.53%
H:
5.23%
C:
-2.49%
disease
alzheimer’s
positive
results
← Previous
1
2
3
4
Next →
Gainers vs Losers
71%
29%
Top 10 Gainers
CZOO
|
$9.98
100.0%
330K
|
AMST
|
$3.48
74.0%
21M
|
Technology Services
BOF
|
$1.78
52.14%
15M
|
CSSE
4
|
$0.2184
43.4%
36M
|
Consumer Services
ACB
|
$7.32
16.56%
780K
|
Process Industries
AEYE
|
$15.42
14.39%
150K
|
Technology Services
CGC
|
$8.835
12.55%
740K
|
Process Industries
BW
|
News
|
$1.0002
9.05%
190K
|
Electronic Technology
DXYZ
4
|
$30.91
8.49%
73K
|
n/a
ANNX
|
$4.78
7.66%
280K
|
Health Technology
Your saved searches
Save your searches and get alerts when important news are released.